Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 3/1999

01-06-1999 | Review

Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state

Author: David Crippen

Published in: Critical Care | Issue 3/1999

Login to get access

Excerpt

The term 'agitation' describes a syndrome of excessive motor activity, usually nonpurposeful and associated with internal tension. For intensivists, agitation is not so much a diagnosis, but a consequence of more fundamental etiologies that, when expressed, result in disquietude. Agitation is important in the intensive care unit (ICU) because it can alter the diagnosis and course of medical treatment. It can cloud the etiology of underlying disease processes like a smoke screen, making effective diagnosis difficult or impossible. It may result in the inability of the patient to cooperate with monitoring and therapeutics that requires them to lie relatively still and quiet. Treatment of agitation without considering underlying causation gives the false impression of wellness when in reality end-organ damage is occurring either as a result of agitation itself, or as a result of exacerbation of underlying pathology. …
Literature
1.
Davidson RJ, Irwin W: The functional neuroanatomy of emotion and affective style. Trends Cogn Sci 1999, 3: 11-21. 10.1016/S1364-6613(98)01265-0PubMed
2.
Kropotov JD, Etlinger SC: Selection of actions in the basal gangliathalamocortical circuits: review and model. Int J Psychophysiol 1999, 31: 197-217. 10.1016/S0167-8760(98)00051-8PubMed
3.
Reid SG, Milsom WK: Respiratory pattern formation in the isolated bullfrog (Rana catesbeiana) brainstem-spinal cord. Respir Physiol 1998, 114: 239-255. 10.1016/S0034-5687(98)00091-7PubMed
4.
Barrera-Mera B, Barrera-Calva E: The Cartesian clock metaphor for pineal gland operation pervades the origin of modern chronobiology. Neurosci Biobehav Rev 1998, 23: 1-4. 10.1016/S0149-7634(97)00062-6PubMed
5.
6.
Smythies J: The functional neuroanatomy of awareness: with a focus on the role of various anatomical systems in the control of intermodal attention. Conscious Cogn 1997, 6: 455-458. 10.1006/ccog.1997.0315PubMed
7.
Philip Strange: Brain Biochemistry and Brain Disorders. Oxford: Oxford University Press; 1992.
8.
Fischer JE, Rosen HM, Ebeid AM, et al.: The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976, 80: 77-91.PubMed
9.
Settipane GA: The restaurant syndromes. N Engl Reg Allergy Proc 1987, 8: 39-46.PubMed
10.
McConalogue K, Grady EF, Minnis J, et al.: Activation and internalization of the mu-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2. Neuroscience 1999, 90: 1051-1059. 10.1016/S0306-4522(98)00514-4PubMedCentralPubMed
11.
Devaud LL, Morrow AL: Gender-selective effects of ethanol dependence on NMDA receptor subunit expression in cerebral cortex, hippocampus and hypothalamus. Eur J Pharmacol 1999, 369: 331-334. 10.1016/S0014-2999(99)00103-XPubMed
12.
Bonci A, Malenka RC: Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. Neurosci 1999, 19: 3723-3730.
13.
Holt RA, Bateson AN, Martin IL: Decreased GABA enhancement of benzodiazepine binding after a single dose of diazepam. J Neurochem 1999, 72: 2219-2222. 10.1046/j.1471-4159.1999.0722219.xPubMed
14.
Crippen DW, Ermakov S: Stress, agitation and brain failure in critical care medicine. Crit Care Q 1992, 15: 52-74.
15.
Rusnak M, Zorad S, Buckendahl P, et al.: Tyrosine hydroxylase mRNA levels in locus ceruleus of rats during adaptation to long-term immobilization stress exposure. Mol Chem Neuropathol 1998, 33: 249-258.PubMed
16.
Dunn AJ: Stress-related changes in cerebral catecholamine and indoleamine metabolism: lack of effect of adrenalectomy and corticosterone. J Neurochem 1988, 51: 406-412.PubMed
17.
Schafers RF, Nurnberger J, Herrmann B, et al.: Adrenoceptors mediating the cardiovascular and metabolic effects of α -methylnoradrenaline in humans. J Pharmacol Exp Ther 1999, 289: 918-925.PubMed
18.
Fontana A, Rosenheck R: A model of war zone stressors and post-traumatic stress disorder. J Trauma Stress 1999, 12: 111-126. 10.1023/A:1024750417154PubMed
19.
Crippen DW: The role of sedation in the ICU patient with pain and agitation. Crit Care Clin 1990, 6: 369-392.PubMed
20.
Bagley J, Moghaddam B: Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997, 77: 65-73. 10.1016/S0306-4522(96)00435-6PubMed
21.
Middleton HC: Panic disorder: a theoretical synthesis of medical and psychological approaches. J Psychosom Res 1998, 44: 121-132. 10.1016/S0022-3999(97)00208-0PubMed
22.
Crippen DW: Pharmacologic treatment of brain failure and delirium. Crit Care Clin 1994, 10: 733-766.PubMed
23.
24.
Szabo ST, de Montigny C, Blier P: Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 1999, 126: 568-571.PubMedCentralPubMed
25.
Buerk DG, Osanai S, Mokashi A, Lahiri S.: Dopamine, sensory discharge, and stimulus interaction with CO 2 and O 2 in cat carotidbody. Appl Physiol 1998, 85: 1719-1726.
26.
Langston P, Gorman D, Runciman W, et al.: The effect of carbon monoxide on oxygen metabolism in the brains of awake sheep. Toxicology 1996, 114: 223-232. 10.1016/S0300-483X(96)03513-5PubMed
27.
Griez E, Schruers K: Experimental pathophysiology of panic. Psychosom Res 1998, 45: 493-503. 10.1016/S0022-3999(98)00027-0
28.
Zangen A, Overstreet DH, Yadid G: Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res 1999, 824: 243-250. 10.1016/S0006-8993(99)01214-7PubMed
29.
Castellano C, Cabib S, Puglisi-Allegra S, et al.: Strain-dependent involvement of D 1 and D 2 dopamine receptors in muscarinic cholinergic influences on memory storage. Behav Brain Res 1999, 98: 17-26. 10.1016/S0166-4328(98)00046-1PubMed
30.
Horger BA, Iyasere CA, Berhow MT, et al.: Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999, 19: 4110-4122.PubMed
31.
Basso AM, Gioino G, Molina VA, et al.: Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pretreatment. Pharmacol Biochem Behav 1999, 62: 307-314. 10.1016/S0091-3057(98)00166-XPubMed
32.
Iturriaga R, Alcayaga J, Zapata P: Dissociation of hypoxia-induced chemosensory responses and catecholamine efflux in cat carotid body superfused in vitro. J Physiol (Lond) 1996, 497: 551-564.
33.
Harrison PJ: The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122: 593-624. 10.1093/brain/122.4.593PubMed
34.
Miller NE, Lipowski JZ, Lebowitz BD: Delirium: Advances in research and Clinical Practice. New York: Springer; 1991.
35.
Crippen DW: Neurologic monitoring in the intensive care unit. New Horizons 1994, 2: 107-120.PubMed
36.
Crippen D: Understanding neurohumoral causes of anxiety in the ICU. J Crit Ill 1995, 10: 550-560.
37.
Settle EC, Ayd FJ: Haloperidol: a quarter century of experience. J Clin Psychiatry 1983, 44: 440-448.PubMed
38.
Tesar GE, Murray GB, Cassem NH: Use of haloperidol for acute delirium in intensive care setting. J Clin Psychopharmacol 1985, 5: 344-347.PubMed
39.
Todd CL, Grace AA: Interaction of benztropine and haloperidol actions on rat substantia nigra dopamine cell electrophysiological activity in vivo. Brain Res Bull 1999, 48: 219-222. 10.1016/S0361-9230(98)00166-XPubMed
40.
Wagner BK, O'Hara DA, Hammond JS: Drugs for amnesia in the ICU. Am J Crit Care 1997, 6: 192-203.PubMed
41.
Gerlach J, Larsen EB: Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 1999, 395: 113-117.PubMed
42.
Rosebush PI, Mazurek MF: Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999, 52: 782-785.PubMed
43.
Cannon JT, Lewis JW, Weinberg VE, et al.: Evidence for the independence of brainstem mechanisms mediating analgesia induced by morphine and two forms of stress. Brain Res 1983, 269: 231-236. 10.1016/0006-8993(83)90132-4PubMed
44.
Rosow C: Agonist-antagonist opioids: theory and clinical practice. Can J Anaesth 1989, 36: S5-8.PubMed
45.
Hughes J, Woodruff GN: Neuropeptides. Function and clinical applications. Arzneimittelforschung 1992, 42: 250-255.PubMed
46.
Field MJ, Carnell AJ, Gonzalez MI, et al.: Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain 1999, 80: 383-389. 10.1016/S0304-3959(98)00237-1PubMed
47.
Watkins LR, Wiertelak EP, McGorry M, et al.: Neurocircuitry of conditioned inhibition of analgesia: effects of amygdala, dorsal raphe, ventral medullary, and spinal cord lesions on antianalgesia in the rat. Behav Neurosci 1998, 112: 360-378. 10.1037//0735-7044.112.2.360PubMed
48.
Furst S: Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999, 48: 129-141. 10.1016/S0361-9230(98)00159-2PubMed
49.
Sahni R, Menegazzi JJ, Mosesso VN Jr: Paramedic evaluation of clinical indicators of cervical spinal injury. Prehosp Emerg Care 1997, 1: 16-18.PubMed
50.
Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Rheumatol 1998, 57 (suppl 2): 81-87. 10.1007/s003930050242
51.
King SM: Escape-related behaviours in an unstable, elevated and exposed environment. II. Long-term sensitization after repetitive electrical stimulation of the rodent midbrain defence system. Behav Brain Res 1999, 98: 127-142. 10.1016/S0166-4328(98)00061-8PubMed
52.
Wang TL, Chang H, Hung CR, et al.: Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. Cardiovasc Res 1998, 40: 557-563. 10.1016/S0008-6363(98)00192-8PubMed
53.
Schlaepfer TE, Strain EC, Greenberg BD, et al.: Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 1998, 155: 470-473.PubMed
54.
Janal MN, Colt EW, Clark WC, Glusman M: Pain sensitivity, mood and plasma endocrine levels in man following long-distance running: effects of naloxone. Pain 1984, 19: 13-25. 10.1016/0304-3959(84)90061-7PubMed
55.
56.
Arief AI, Griggs RC: Metabolic Brain Dysfunction in Systemic Disorders.Boston: Little, Brown Co.; 1992.
57.
Casadevall M, Saperas E, Panes J, et al.: Mechanisms underlying the anti-inflammatory actions of central corticotropin-releasing factor. Am J Physiol 1999, 276: G1016-G1026.PubMed
58.
Ignar DM, Kuhn CM: Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. Pharmacol Exp Ther 1990, 255: 1287-1295.
59.
Marti O, Harbuz MS, Andres R, et al.: Activation of the hypothalamic–pituitary axis in adrenalectomised rats: potentiation by chronic stress. Brian Res 1999, 821: 1-7. 10.1016/S0006-8993(98)01212-8
60.
Marti O, Harbuz MS, Andres R, et al.: Activation of the hypothalamic-pituitary axis in adrenalectomised rats: potentiation by chronic stress. Brain Res 1999, 821: 1-7. 10.1016/S0006-8993(98)01212-8PubMed
61.
Bremner JD: Does stress damage the brain? Biol Psychiatry 1999, 45: 797-805. 10.1016/S0006-3223(99)00009-8PubMed
62.
Hashimoto K, Suemaru S, Takao T, et al.: Corticotropin-releasing hormone and pituitary–adrenocortical responses in chronically stressed rats. Regul Pept 1988, 23: 117-126. 10.1016/0167-0115(88)90019-5PubMed
63.
To CT, Bagdy G: Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 1999, 38: 279-282. 10.1016/S0028-3908(98)00176-2PubMed
64.
Hotta M, Shibasaki T, Arai K, et al.: Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res 1999, 823: 221-225. 10.1016/S0006-8993(99)01177-4PubMed
65.
Marshall SB, Marshall LF, . Neuroscience Critical Care: Pathophysiology and Patient Management. Philadelphia: WB Saunders; 1990.
66.
Arnsten AF: Catecholamine regulation of the prefrontal cortex. Psychopharmacology 1997, 11: 151-162.
67.
Gorman AL, Dunn AJ: β-Adrenergic receptors are involved in stress-related behavioral changes. Pharmacol Biochem Behav 1993, 45: 1-7. 10.1016/0091-3057(93)90078-8PubMed
68.
Khasar SG, McCarter G, Levine JD: Epinephrine produces a β-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 1999, 81: 1104-1112.PubMed
69.
Gray AM: Effect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study. Eur J Pharmacol 1996, 313: 73-77. 10.1016/0014-2999(96)00599-7PubMed
70.
Sidebotham D, Dijkhuizen MR, Schug SA: The safety and utilization of patient-controlled analgesia. Pain Symptom Manage 1997, 14: 202-209. 10.1016/S0885-3924(97)00182-6
71.
Gan TJ, Ginsberg B, Glass PS, et al.: Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997, 87: 1075-1081. 10.1097/00000542-199711000-00011PubMed
72.
Katcher J, Walsh D: Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. Pain Symptom Manage 1999, 17: 70-72. 10.1016/S0885-3924(98)00115-8
73.
Fleischmann E, Akca O, Wallner T, et al.: Onset time, recovery duration, and drug cost with four different methods of inducing general anesthesia. Anesth Analg 1999, 88: 930-935.PubMed
74.
Byun MY, Fine NA, Lee JY, et al.: The clinical outcome of abdominoplasty performed under conscious sedation: increased use of fentanyl correlated with longer stay in outpatient unit. Plast Reconstr Surg 1999, 103: 1260-1266.PubMed
75.
Jung D, Mroszczak E, Bynum L: Pharmacokinetics of ketorolac in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 1988, 35: 423-425.PubMed
76.
Bravo LJ, Mattie H, Spierdijk J: The effects on ventilation of ketorolac in comparison with morphine. Eur J Clin Pharmacol 1988, 35: 491-494.PubMed
77.
Barvais L, Dejonckheere M, Dernovoi B, et al.: Continuous infusion of midazolam or bolus of diazepam for postoperative sedation cardiac surgical patients. Acta Anaesthesiol Belgica 1988, 39:: 239-245.
78.
Behne M, Asskali F, Steuer , et al.: Continuous midazolam infusion for sedation of respirator patients. Anesthetist 1987, 36: 228-232.
79.
Coenen AM, van Luijtelaar EL: Effects of benzodiazepines, sleep and sleep deprivation on vigilance and memory. Acta Neurol Belg 1997, 97: 123-129.PubMed
80.
Shafer A: Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998, 26: 947-956. 10.1097/00003246-199805000-00034PubMed
81.
Nordt SP, Clark RF: Midazolam: a review of therapeutic uses and toxicity. Emerg Med 1997, 15: 357-365. 10.1016/S0736-4679(97)00022-X
82.
Sperlagh B, Sershen H, Lajtha A, et al.: Co-release of endogenous ATP and [ 3 H]noradrenaline from rat hypothalamic slices: origin and modulation by α 2 - adrenoceptors. Neuroscience 1998, 82: 511-520. 10.1016/S0306-4522(97)00306-0PubMed
83.
Boher H, Bach A, Layer M, et al.: Clonidine as a sedative adjunct. Intensive Care Med 1990, 16: 265-266.
84.
Kulkarni SK, Parale MP, Kulkarni GK: Clonidine in alcohol withdrawal: a clinical report. Methods Find Exp Clin Pharmacol 1987, 9: 697-698.PubMed
85.
Nutt D, Glue P, Molyneux S, et al.: α-2-Adrenoceptor function in alcohol withdrawal: a pilot study of the effects of iv. clonidine in alcoholics and normals. Alcohol Clin Exp Res 1988, 12: 14-18.PubMed
86.
Wing LM, Reid JL, Hamilton CA, et al.: Effects of clonidine on biochemical indices of sympathetic function in normotensive man. Clin Sci Mol Med 1977, 53: 45-53.PubMed
87.
Ghignone M, Quintin L, Kehler CH, et al.: Effects of clonidine on narcotic requirements and hemodynamic response during indduction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 1986, 64: 36-42.PubMed
88.
Coombs DW, Saunders RL, Fratkin JD, et al.: Continuous intrathecal hydromorphone and clonidine for tractable cancer pain. J Neurosurg 1986, 64: 890-894.PubMed
89.
Cushman PJ, Sowers JR: Alcohol withdrawal syndrome: clinical and hormonal responses to α-2 adrenergic treatment. Alcoholism 1989, 13: 361-364.PubMed
90.
Hokfelt B, Hedeland H, Hasson BG: The effect of clonidine and penbutol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch Int Pharmacodyn 1975, 213: 307-321.PubMed
91.
Toon S, Hopkins KJ, Aarons L, Rowland M: Rate and extent of absorption of clonidine from a transdermal therapeutic system. J Pharm Pharmacol 1989, 41: 17-21.PubMed
92.
Bernard JM, Hommeril JL, Passuti N, Pinaud M: Postoperative analgesia by intravenous clonidine. Anesthesiology 1991, 75: 577-582.PubMed
93.
Aantaa RE, Kanto JH, Scheinin M: Dexmedetomidine premedication for minor gynecologic surgery. Anesth Analg 1990, 4: 407-413.
94.
Aantaa RE, Kanto JH: Dexmedotomidine, an α 2 -adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. Anesthesiology 1990, 73: 230-235.PubMed
95.
Lane R, Baldwin D: Selective serotonin reuptake inhibitor-induced serotonin syndrome [review]. J Clin Psychopharmacol 1997, 17: 208-221. 10.1097/00004714-199706000-00012PubMed
96.
Silver H, Shmugliakov N: Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998, 18: 208-211. 10.1097/00004714-199806000-00005PubMed
97.
Davidson C, Stamford JA: Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT 1 A , 5-HT 1 B and 5-HT 1 D autoreceptors. Br J Pharmacol 1995, 114: 1107-1109.PubMedCentralPubMed
98.
Hery F, Boulenguez P, Semont A, et al.: Identification and role of serotonin 5-HT 1A and 5-HT 1B receptors in primary cultures of rat embryonic rostral raphe nucleus neurons. Neurochem 1999, 72: 1791-1801. 10.1046/j.1471-4159.1999.0721791.x
99.
Yocca FD: Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. Clin Psychopharmacol 1990, 10 (suppl 3): 6S-12S.
100.
Hashimoto T, Hamada C, Wada T, et al.: Comparative study on the behavioral and EEG changes induced by diazepam, buspirone and a novel anxioselective anxiolytic, DN- in the cat. Neuropsychobiology 1992, 26: 89-99.PubMed
101.
Kato M, Kajimura N, Okuma T, et al.: Association between delta waves during sleep and negative symptoms in schizophrenia.Pharmaco-EEG studies by using structurally different hypnotics. Neuropsychobiology 1999, 39: 165-172. 10.1159/000026577PubMed
102.
Yoshimoto M, Higuchi H, Kamata M, et al.: The effects of benzodiazepine (triazolam), cyclopyrrolone (zopiclone) and imidazopyridine (zolpidem) hypnotics on the frequency of hippocampal theta activity and sleep structure in rats. Eur Neuropsychopharmacol 1999, 9: 29-35. 10.1016/S0924-977X(97)00102-8PubMed
103.
Lancel M: Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep 1999, 22: 33-42.PubMed
104.
Strohle A, Antonijevic IA, Steiger A, et al.: Dependency of non-benzodiazepine hypnotics. Two case reports. Nervenarzt 1999, 70: 72-75. 10.1007/s001150050403PubMed
105.
Concas A, Serra M, Santoro G, et al.: The effect of cyclopyrrolones on GABA A receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1994, 350: 294-300.PubMed
106.
Wong G, Uusi-Oukari M, Hansen HC, et al.: Characterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors. Eur J Pharmacol 1995, 289: 335-342. 10.1016/0922-4106(95)90111-6PubMed
107.
Revel L, Mennuni L, Garofalo P, et al.: CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 1998, 9: 183-194.PubMed
108.
Maletinska L, Pirkova J, Hlavacek J, et al.: Cholecystokinin analogs with suppressed central activities. Peptides 1998, 19: 301-308. 10.1016/S0196-9781(97)00371-9PubMed
109.
Dethloff LA, Barr BM, Bestervelt LL: Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988. Food Chem Toxicol 1999, 37: 105-110. 10.1016/S0278-6915(98)00119-7PubMed
110.
Acosta GB: Administration of cholecystokinin sulphated octapeptide (CCK-8S) induces changes on rat amino acid tissue levels and on a behavioral test for anxiety. Gen Pharmacol 1998, 31: 637-641. 10.1016/S0306-3623(98)00075-5PubMed
111.
Lofberg C, Agren H, Harro J, et al.: Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. Eur Neuropsychopharmacol 1998, 8: 153-157. 10.1016/S0924-977X(97)00046-1PubMed
112.
Crespi F: Cholecystokinin-B (CCK-B) receptor antagonists improve 'aged' sleep: a new class of sleep modulators? Methods Find Exp Clin Pharmacol 1999, 21: 31-38.PubMed
113.
Singh L, Field MJ, Hughes J, et al.: The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br J Pharmacol 1991, 104: 239-245.PubMedCentralPubMed
114.
Brawman-Mintzer O, Lydiard RB, Bradwejn J, et al.: Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 1997, 154: 700-702.PubMed
115.
Biro E, Sarnyai Z, Penke B, et al.: Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 1993, 57: 340-345.PubMed
116.
Singh L, Field MJ, Hill DR, et al.: Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Eur J Pharmacol 1995, 286: 185-191. 10.1016/0014-2999(95)00445-QPubMed
117.
Ohtsuka T, Nakayama N, Itezono Y, et al.: Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. III. Structural elucidation. J Antibiot (Tokyo) 1993, 46: 18-24.
Metadata
Title
Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state
Author
David Crippen
Publication date
01-06-1999
Publisher
BioMed Central
Published in
Critical Care / Issue 3/1999
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc348

Other articles of this Issue 3/1999

Critical Care 3/1999 Go to the issue

Research

Low systemic vascular resistance: differential diagnosis and outcome

Commentary

Informed consent and research design in critical care medicine

Research

Effects on respiratory function of the head-down position and the complete covering of the face by drapes during insertion of the monitoring catheters in the cardiosurgical patient

Commentary

Crystalloid or colloid for resuscitation. Are we any the wiser?

Research

A prospective randomised pilot study of sedation regimens in a general ICU population: a reality-based medicine study